Antibody-based methods targeting HSCs are advancing to patients, with the most advanced antagonistic anti-CD117 naked antibody derived from our prior work already in clinical trials in severe combined immunodeficiency patients which is showing encouraging clinical results21. The gene discussed is KIT; the disease is severe combined immunodeficiency.